Chemical compounds

US11702405B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Ariamala Gopalsamy · Lexington, US
• Shawn Cabral · Groton, US
• Agustin Casimiro-Garcia · Concord, US
• Ming Zhu Chen · Mystic, US
• Chulho Choi · Mystic, US
• Robert L. Dow · Waterford, US
• Olugbeminiyi Omezia Fadeyi · Harvard, US
• David Hepworth · Concord, US
• Jayasankar Jasti · East Lyme, US
• Lyn Howard Jones · Canterbury, GB
• Arjun Venkat Narayanan · Cambridge, US
• Mihir Dineshkumar Parikh · Davisville, US
• David W. Piotrowski · Waterford, US
• Lee Richard Roberts · Chatham, GB
• Ralph P. Robinson · Gales Ferry, US
• Hatice Gizem Yayla · Mystic, US

Key dates

• Filing date: Apr 12, 2021
• Grant date: Jul 18, 2023
• Expiry date: Oct 9, 2041

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).